French drugmaker Sanofi said on Friday it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. ...

Core Points - Sanofi US has expanded its Insulins Valyou Savings Program to offer a 30-day supply of any Sanofi insulin for $35 to all patients in the US with a valid prescription, regardless of insurance status [1][2][4] - The program aims to ensure that no American pays more than $35 per month for Sanofi insulins, addressing a critical healthcare issue for millions living with diabetes [2][5] - The initiative is a continuation of efforts to lower costs for American patients, aligning with previous healthcare objectives [3][5] Program Details - The expanded program will cover all types and combinations of Sanofi insulins and will be implemented nationwide starting January 1, 2026 [4][5] - Patients can enroll in the program through Sanofi Patient Connection or by calling a designated number [5] - The program is designed to work at most pharmacies across the US, including independent and rural pharmacies, without creating complex hurdles for patients [3][4] Company Commitment - Sanofi emphasizes its commitment to improving access and affordability for diabetes management, highlighting the importance of consistent access to medication [5] - The company plans to continue collaborating with policymakers and stakeholders to develop sustainable, long-term solutions for healthcare access [3][5] - Sanofi's initiatives reflect its broader mission to address urgent healthcare challenges and improve the lives of people affected by diabetes [6]

Core Points - President Trump's decision to impose a 100% tariff on imported branded pharmaceuticals starting October 1, 2025, is expected to significantly impact American consumers and global drug stocks, although there are exemptions for companies building manufacturing plants in the U.S. [1][2] - The tariff is anticipated to create a meaningful commercial hit for U.S. consumers, as over 20% of U.S. pharmaceutical imports by value come from Asia [6]. Industry Impact - Asian drug companies experienced a decline in market capitalization as traders reacted negatively to the news, with significant losses reported in Japan's pharmaceutical sector [4][3]. - In Europe, companies like Novo Nordisk and Roche saw minor declines, while Sanofi experienced a slight increase, which may be a temporary rebound after a previous loss [5]. - U.S. pharmaceutical stocks, including Pfizer, Eli Lilly, and Bristol-Myers Squibb, showed marginal gains in premarket trading, indicating a mixed reaction to the tariff announcement [5]. Economic Analysis - Analysts from Oxford Economics highlighted that the tariffs would pose a substantial commercial challenge for U.S. consumers, but they also suggested that the White House may need to relax some standards to mitigate the impact [2][6]. - The imposition of tariffs is part of a broader trade war context, which has already affected market performance in Asia, particularly in the pharmaceutical sector [4].

两项研究拟纳入1884例患者，旨在评估Lunsekimig(两个剂量，皮下注射)对比安慰剂治疗控制不佳的嗜 酸性粒细胞表型COPD成人患者的有效性和安全性。研究的主要终点为基线至第48周中重度COPD恶化 的年化发生率。 此前，赛诺菲曾公布Lunsekimig治疗哮喘的Ib期概念验证研究数据。数据显示，哮喘患者经400mg Lunsekimig治疗28天后，呼出一氧化碳分数(FENO)较基线显著降低，较安慰剂组降幅为 40.9ppb(p<0.0001)。此外，患者的2型炎症反应生物标志物水平亦显著降低。 （原标题：赛诺菲(SNY.US)TSLP/IL-13双抗启动COPD II/III期临床） 智通财经APP获悉，9月24日，全球临床试验收录网站显示，赛诺菲(SNY.US)的TSLP/IL-13双抗 Lunsekimig(SAR443765)推进至II/III期阶段，针对慢性阻塞性肺病(COPD)启动了两项II/III期临床试验 (THESEUS和PERSEPHONE)。 ...

Core Points - Immuneering Corporation has priced its underwritten public offering of 18,959,914 shares of Class A common stock at $9.23 per share, with gross proceeds expected to be approximately $175 million before deductions [1][2] - Sanofi has agreed to purchase 2,708,559 shares of Immuneering's Class A common stock at the same price in a separate private placement transaction [1] - The public offering and private placement are expected to close concurrently on or about September 26, 2025, subject to customary closing conditions [1] Use of Proceeds - The net proceeds from the public offering and private placement will be used to advance the preclinical and clinical development of Immuneering's product candidates, as well as for working capital and other general corporate purposes [2] Offering Details - The public offering is made pursuant to a shelf registration statement on Form S-3, which was filed with the SEC on August 13, 2025, and declared effective on August 20, 2025 [3] - A prospectus supplement relating to the offering will be filed with the SEC [3] Private Placement - The shares sold in the private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the U.S. without registration or an applicable exemption [4]

Core Viewpoint - Immuneering Corporation has announced a proposed underwritten public offering of its Class A common stock and a concurrent private placement with Sanofi for $25 million, aimed at advancing its oncology product candidates and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes shares of Class A common stock and pre-funded warrants, with underwriters granted a 30-day option to purchase an additional 15% of the offered shares [1]. - Sanofi will purchase $25 million worth of Immuneering's Class A common stock or non-voting Class B common stock at the public offering price, in a private placement expected to close concurrently with the public offering [1][2]. - The offering is subject to market conditions and the private placement is contingent upon the closing of the public offering [1]. Group 2: Use of Proceeds - The net proceeds from both the public offering and private placement will be utilized to advance preclinical and clinical development of product candidates, as well as for working capital and other general corporate purposes [2]. Group 3: Regulatory Information - The offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on August 20, 2025 [3]. - A preliminary prospectus supplement will be filed with the SEC, and copies will be available through the underwriters [3][7]. Group 4: Securities Registration - The shares sold in the private placement will not be registered under the Securities Act of 1933 and cannot be offered or sold in the U.S. without registration or an applicable exemption [4].

A Paris court on Wednesday ordered Sanofi and its Winthrop unit to pay 150.7 million euros ($177.1 million) in damages to France's national health insurance fund (CNAM) for anti-competitive practices ... ...

Commerzbank said on Wednesday that it would begin to buy back up to 1 billion euros ($1.18 billion) in shares starting on Thursday, a move that comes as it seeks to remain independent with Italy's Uni... ...

Summary of Royalty Pharma FY Conference Call Company Overview - **Company**: Royalty Pharma (NasdaqGS:RPRX) - **Industry**: Biopharmaceutical royalties - **Market Position**: Largest buyer of biopharmaceutical royalties globally with over 50 products in its portfolio [7][9] - **Financial Metrics**: - Portfolio receipts guidance for 2025: $3.1 billion - Cash flow guidance for 2025: $2.5 billion - Market capitalization: over $20 billion - CAGR of royalty receipts: 12% since IPO [9][10][21] Core Business Model - **Investment Strategy**: Focus on high-quality, important medicines with strong data; operates as a generalist team to evaluate diverse therapeutic areas [16][27][29] - **Capital Allocation**: - $14 billion deployed since IPO - $4 billion returned through buybacks and repurchases [10][11] - **Royalty Types**: - Traditional royalties from licensing transactions - Synthetic royalties created through direct investments in companies [19][20] Growth and Market Dynamics - **Market Expansion**: Significant growth in biotech innovation leading to increased demand for diverse capital sources [11][12] - **Financial Targets**: - Portfolio receipt CAGR target of 10% or more from 2020 to 2030, currently tracking at 12% [21] - Capital deployment target of $10 billion to $12 billion over five years, already exceeding this target [22] - **Investment Returns**: - Unlevered IRR targets: high single to low double digits for approved products, teens for development stage products [23][24] Recent Transactions and Innovations - **Revolution Medicines Deal**: - $2 billion partnership allowing Revolution Medicines to maintain independence while providing significant capital for development [45][50] - Unique structure with upfront and milestone-based funding, including senior secured debt [51][52] - **Investment in Diverse Areas**: - Focus on underrepresented therapeutic areas such as migraine and psychiatry, with investments in CGRP and long-acting injectable products [36][37] Competitive Landscape - **Market Positioning**: - Unique evergreen business model allowing for lower cost of capital and flexibility in investments [40][41] - Emphasis on creating a vibrant marketplace for royalties, welcoming competition while maintaining a leadership position [43][44] Future Outlook - **Market Opportunities**: - Fragmentation in the biotech sector and increased innovation create ongoing opportunities for royalty transactions [58][59] - Potential for new royalties from licensing activities in emerging markets like China [62] - **Deal Structure Innovations**: - Plans to explore earlier-stage investments and innovative funding structures to adapt to market needs [71][72] Key Takeaways - Royalty Pharma is well-positioned in a growing market with a strong track record of capital allocation and investment returns - The company is focused on maintaining its leadership in the biopharmaceutical royalty space through innovative deal structures and strategic partnerships - Future growth is anticipated through continued investment in diverse therapeutic areas and adapting to market dynamics

Group 1 - The company has made significant advancements in its pipeline, although there were mixed results from the itepekimab readout, which has created a complicated situation [2] - The company is optimistic about the feedback received for amlitelimab and is excited about developments in the immunology marketplace [2] - The extension of the PDUFA for tolebrutinib is seen positively, as the company prefers a thorough review of data over a rushed decision [3] Group 2 - The underlying performance of the company is reported to be strong [4]